SPPAM
ENZY

Summit Partners Public Asset Management’s Enzymotec Ltd ENZY Stock Holding History

Summit Partners Public Asset Management’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-96,600
Closed -$874K – 78
2015
Q3 		$874K Buy
96,600
+5,640
+6% +$50.3K 0.33% 50
2015
Q2 		$760K Buy
+90,960
New +$835K 0.27% 62

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Summit Partners Public Asset Management's ENZY Position: Q4 2015 in Review

Summit Partners Public Asset Management sold out of Enzymotec Ltd (ENZY) in Q4 2015, closing a stake of 96,600 shares — an estimated $874K sold.

Summit Partners Public Asset Management first reported a position in ENZY in Q2 2015 and held it in 2 quarters. The position peaked at $874K in Q3 2015. 30 funds tracked by Wall St. Rank hold ENZY as of Q4 2015.

  • Summit Partners Public Asset Management reported no remaining Enzymotec Ltd position as of Q4 2015 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 96,600 Enzymotec Ltd shares in Q4 2015, an estimated $874K.
  • Summit Partners Public Asset Management first reported a position in Enzymotec Ltd in Q2 2015 and held it in 2 quarters.
  • Summit Partners Public Asset Management's Enzymotec Ltd position peaked at $874K in Q3 2015.
  • 30 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q4 2015.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.